ETReaCOPD: Effects of Elastic Tape on Pulmonary Rehabilitation of Patients With Chronic Obstructive Pulmonary Disease

Sponsor
University of Sao Paulo General Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05939999
Collaborator
(none)
42
1
2
11
3.8

Study Details

Study Description

Brief Summary

Evaluate the effect of the use of elastic tape in chest wall and abdomen in the physical capacity, psychosocial distress levels, quality of life and anxiety, and depression symptoms of individuals with moderate to very severe COPD undergoing pulmonary rehabilitation.

Condition or Disease Intervention/Treatment Phase
  • Other: Experimental: Elastic tape (ET)
  • Other: Sham Comparator: Sham (SH)
N/A

Detailed Description

Individuals will be evaluated on two non-consecutive days (7 days apart). On the first visit, wil be obtained: clinical and anthropometric data and assessed clinical control [COPD Assessment Test™(CAT)], health-related quality of life [Chronic Respiratory Questionnaire (CRQ)], and anxiety and depression levels [Hospital Anxiety and Depression Scale (HADS)]. Patients will also perform a complete pulmonary function test. After, the volunteers will receive a triaxial accelerometer to assess their physical activity level (PAL) and will be instructed to return after seven days. On the second visit, patients will undergo the Incremental Shuttle Walking Test (ISWT), and the Endurance Shuttle Walking Test (ESWT), without ET.

After the assessments, the individuals will be randomized. Randomization will be computer generated (www.randomization.com) by an investigator who will not be involved in individual recruitment, evaluation, or intervention. The allocation of individuals will be secret using consecutive numbered, sealed, and opaque envelopes (concealed allocation). Initial and post-intervention assessments will be performed by an investigator who will not be involved in the recruitment, evaluation, or intervention. After inclusion, individuals will start a pulmonary rehabilitation (PR) program for eight weeks; twice a week, individuals in the ET group will have the tape applied at the beginning of each session and removed at the end. After completing the 8-week PR period, individuals will undergo the same tests performed in two visits.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
42 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Masking Description:
Evaluations will be conducted blindly, that is, by an evaluator who will not be directly involved in the intervention.
Primary Purpose:
Treatment
Official Title:
Effects of Elastic Tape on Pulmonary Rehabilitation of Patients With Chronic Obstructive Pulmonary Disease
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Elastic tape (ET)

The group that will participate in the 8 weeks pulmonary rehabilitation protocol using the elastic tape.

Other: Experimental: Elastic tape (ET)
The elastic tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.

Sham Comparator: Sham (SH)

The group that will participate in the pulmonary rehabilitation protocol using micropore tape.

Other: Sham Comparator: Sham (SH)
The micropore tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.

Outcome Measures

Primary Outcome Measures

  1. FUNCTIONAL EXERCISE CAPACITY [Change from baseline at 8 weeks of intervention.]

    The total time reachead in the Endurance Shuttle Walking Test (ESWT). The patients will be instructed to walk in a 10-meter corridor limited by cones (with a distance of 9 meters between them), and the speed will be determined by a sound signal recordes on CD, in this case, the speed will be determined using 85% of the maximum speed reached in the Incremental Shuttle Walking Test (ISWT) and will be constant throughout the test.

Secondary Outcome Measures

  1. CLINICAL CONTROL [Change from baseline at 8 weeks of intervention.]

    COPD Assessment Test™ (CAT) is a specific questionnaire for COPD that assesses the impact of the symptoms of the disease. It consists of eight items related to the health condition and is applied and validated worldwide in several langues. The maximum test score is 40 points, and the questions cover follow symptoms: cough, phlegm production, chest pressure, shortness of breath, activities of daily living, psychological aspects, sleep, and mood. Each question has six options (0-5), and the lower the score, the better the health condition.

  2. SYMPTOMS OF ANXIETY AND DEPRESSION [Change from baseline at 8 weeks of intervention.]

    Hospital Anxiety and Depression Scale (HADS): The questionnaire was developed to identify symptoms of anxiety and depressive mood. It consists of 14 multiple-choice questions divided into two subscales: anxiety (HADS-A) and depression (HADS-D), with seven questions each. The domains are categorized by the severity of the stress present: 0-7 - none; 8-10 - likely; >11 - present.

  3. HEALTH-RELATED QUALITY OF LIFE [Change from baseline at 8 weeks of intervention.]

    Disease-specific HRQoL was assessed by using the Chronic Respiratory Questionnaire (CRQ): This questionnaire consists of 20 questions, divided into four domains: Fatigue (4 questions), Emotional Function (7 questions), and Self-control (4 questions) evaluated using a Likert scale with seven alternatives ranging from "never" to "always." The dyspnea domain (5 questions) has an individualized assessment in which the individual chooses from a list of 26 daily activities which are the five activities that most cause dyspnea and then grades each one again using a Likert scale with seven alternatives ranging from "unbearable shortness of breath" to "No shortness of breath." Results are expressed as the average score for each domain and the total score, and higher scores indicate a better health-related quality of life.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Moderate to very severe COPD diagnosis according to GOLD 2020

  • Clinical stability (i.e., no exacerbations for at least 30 days)

  • Male

  • Non-obese (BMI ≤29.9 kg/m2)

  • No musculoskeletal limitation

  • Not included in a pulmonary rehabilitation program in the last 6 months.

  • Do not perform home oxygen therapy

Exclusion Criteria:
  • Present osteoarticular, cognitive, neurological, and/or cardiological dysfunctions that prevent physical training

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinical Hospital of São Paulo University medical school (HCFMUSP) São Paulo Brazil 05360-160

Sponsors and Collaborators

  • University of Sao Paulo General Hospital

Investigators

  • Study Director: Celso RF Carvalho, University of Sao Paulo General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Sao Paulo General Hospital
ClinicalTrials.gov Identifier:
NCT05939999
Other Study ID Numbers:
  • 2022/09628-1
First Posted:
Jul 11, 2023
Last Update Posted:
Jul 11, 2023
Last Verified:
Jun 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Sao Paulo General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 11, 2023